Home/Filings/4/0001493152-25-003181
4//SEC Filing

Bernards Rene 4

Accession 0001493152-25-003181

CIK 0001335105other

Filed

Jan 21, 7:00 PM ET

Accepted

Jan 22, 1:13 PM ET

Size

9.2 KB

Accession

0001493152-25-003181

Insider Transaction Report

Form 4
Period: 2025-01-20
Transactions
  • Award

    Options to Purchase Common Stock

    2025-01-20+4,1664,166 total
    Exercise: $2.33From: 2025-01-20Exp: 2030-01-20Common (4,166 underlying)
Holdings
  • Options to Purchase Common Stock

    Exercise: $1.30From: 2024-09-30Exp: 2029-09-30Common (5,304 underlying)
    5,304
  • Options to Purchase Common Stock

    Exercise: $2.37From: 2024-06-30Exp: 2029-06-30Common (10,000 underlying)
    10,000
  • Options to Purchase Common Stock

    Exercise: $2.37From: 2024-06-30Exp: 2029-06-30Common (4,149 underlying)
    4,149
Footnotes (1)
  • [F1]Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 4,166 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Documents

1 file

Issuer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CIK 0001335105

Entity typeother

Related Parties

1
  • filerCIK 0001939159

Filing Metadata

Form type
4
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 1:13 PM ET
Size
9.2 KB